Statistics for Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer
Total visits
| views | |
|---|---|
| Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer | 1 |
Total visits per month
| views | |
|---|---|
| January 2026 | 0 |
| February 2026 | 0 |
| March 2026 | 0 |
| April 2026 | 0 |
| May 2026 | 1 |
| June 2026 | 0 |
| July 2026 | 0 |
File Visits
| views | |
|---|---|
| goldman_jonathan_Invest.New.Drugs_2018.pdf | 42 |
Top country views
| views | |
|---|---|
| United States | 1 |
Top city views
| views | |
|---|---|
| Redmond (Downtown) | 1 |